![Joseph Shulman](data:image/svg+xml,<svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" fill="%231b1b1b" class="bi bi-person-fill" viewBox="0 0 16 16"><path d="M3 14s-1 0-1-1 1-4 6-4 6 3 6 4-1 1-1 1zm5-6a3 3 0 1 0 0-6 3 3 0 0 0 0 6"/></svg>)
Joseph Shulman
Directeur Technique/Scientifique/R&D chez
RHYTHM PHARMACEUTICALS, INC.
Fortune : 2 M $ au 30/06/2026
Profil
Joseph Shulman is Chief Technical Officer at Rhythm Pharmaceuticals, Inc. since 2022, with employment at the company starting in 2020.
Formerly, Mr. Shulman was Senior Vice President-Technical Operations at RA Pharmaceuticals, Inc. from 2019 to 2020 and Senior Vice President-Global Technical Operations at Novelion Therapeutics, Inc. from 2014 to 2019.
Education includes an MBA from Boston University and an undergraduate degree from the University of Miami.
Détentions connues dans des sociétés publiques
| Société | Date | Nombre d'actions | Valorisation | Date de valorisation |
|---|---|---|---|---|
| 11/02/2026 | 18 970 ( 0,03% ) | 2 M $ | 30/06/2026 |
Postes actifs de Joseph Shulman
| Sociétés | Poste | Début |
|---|---|---|
| RHYTHM PHARMACEUTICALS, INC. | Directeur Technique/Scientifique/R&D | 27/07/2020 |
Anciens postes connus de Joseph Shulman
| Sociétés | Poste | Fin |
|---|---|---|
| RA PHARMACEUTICALS, INC. | Directeur Technique/Scientifique/R&D | 01/07/2020 |
| NOVELION THERAPEUTICS INC. | Directeur Technique/Scientifique/R&D | 01/07/2019 |
Formation de Joseph Shulman
Expériences
Fonctions occupées
Actives
Inactives
Sociétés cotées
Entreprise privées
Relations
29
Relations au 1er degré
5
Entreprises liées au 1er degré
Homme
Femme
Administrateurs
Exécutifs
Sociétés liées
| Entreprise privées | 5 |
|---|---|
Ra Pharmaceuticals, Inc.
 Ra Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Develops drugs for the treatment of glomerulonephritis, kidney disease and cardiovascular disease | Health Technology |
Rhythm Pharmaceuticals, Inc.
 Rhythm Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Develops and supplies peptide therapeutics for rare neuroendocrine diseases | Health Technology |
Boston University
 Boston University Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
University of Miami
 University of Miami Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
Novelion Therapeutics, Inc.
 Novelion Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Develops, manufactures and markets rare disease products, metreleptin and lomitapide | Health Technology |
Choisissez Zonebourse 
